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Pregnancy is a state of hypercoagulation, most likely an 
adaptive mechanism, in order to reduce the risk of 
hemorrhage during and after the delivery. There are 
substantial changes in the haemostatic system during 
normal healthy pregnancy including rise in clotting factors 
I, VII, VIII, IX, and X, diminished protein S and fibrinolytic 
activity and resistance to activated protein C.¹ Reduced 
fibrinolytic activity is due to fivefold increase in PAI-1 
(Plasminogen Activator Inhibitor type 1) levels.²  In 
addition venous stasis increases during pregnancy as the 
lower-extremity veins dilate due to venous compression 
by the gravid uterus. Endothelial injury may also occur in 
antepartum or in postpartum period. The combination of 
these factors results in 4-5 times increased risk of venous 
thromboembolism (VTE) in the pregnant and postpartum 
patients.3 The prevalence of VTE in pregnancy is 0.8-2.0 
per 1,000 pregnancies and accounts for 1.1 deaths per 
100,000 pregnancies.4 The most important risk factor for 
women experiencing pregnancy-related VTE is prior 
personal history of VTE.5  The second most common risk 
factor is thrombophilia  6 7  Studies have shown that at 
least 20%, and possibly over 50%, of pregnant patients 
diagnosed with VTE have thrombophilia.8  There is a 
growing evidence that women with thrombophilia are  also 
at risk of other vascular pregnancy complications, 
including recurrent fetal loss, pre‐eclampsia, stillbirths, 
abruption and intrauterine growth restriction. 
Thrombophilia can be Inherited or acquired. Inherited 
Thrombophilias are a group of genetic disorders, which 
can be classified as low or high risk based on the relative 
increased risk of VTE.  
Antiphospholipid antibody syndrome is considered as an 
acquired thrombophilia and its diagnosis is based upon 
clinical history and laboratory testing. Low-risk inherited 
thrombophilias include Heterozygous factor V Leiden, 
Heterozygous prothrombin G20210A mutation, Protein S 
deficiency and Protein C deficiency. High-risk inherited 
thrombophilias include Homozygous factor V Leiden, 
Homozygous prothrombin G20210A mutation, Compound 
heterozygous factor V Leiden with prothrombin mutation 
and Antithrombin deficiency. Ideally, evaluation for 
thrombophilia should be done when the patient is not 
pregnant, does not have an acute thrombotic event, and 
is not on anticoagulation therapy. ACOG (American 
College of Obstetricians and Gynecologists) recommends 
screening a patient for thrombophilia during pregnancy 
only if test results are likely to alter management. 
Screening should be performed when the presence of a 
thrombophilia may alter the intensity or duration of 
anticoagulation therapy. Screening is unnecessary when 
treatment is indicated for other reasons.9 Thrombophilia 
screening may be considered in: 
• Patients with a personal history of VTE that 
occurred in the setting of a transient 
nonrecurrent risk factor (eg, fractures, surgery, 
prolonged immobility) that was not estrogen- or 
pregnancy-related  
• Patients with a first-degree relative with a prior 
VTE that occurred before age 50 years or with a 
prior diagnosis of high-risk thrombophilia. 
Following are the recommended methods of evaluation of 
inherited thrombophilias in pregnancy: 
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• Factor V Leiden: Second-generation activated 
protein C resistance assay is reliable in 
pregnancy; if results are abnormal, evaluate for 
genotype for factor V Leiden mutation; if the 
patient is on anticoagulation therapy, consider 
evaluation of factor V Leiden mutation via 
genotype testing. 
• Prothrombin G20210A mutation DNA analysis 
• Protein C functional activity level 
• Protein S free, total, and functional levels. 
(Protein S deficiency testing is less reliable in 
pregnancy, as levels decrease with increasing 
gestational age).  
• Antithrombin-heparin cofactor assay 
For Antiphospholipid antibody syndrome, in addition to 
specific clinical criteria for evaluation, laboratory criteria 
includes any one of the following (these laboratory 
findings must be abnormal twice, at least 12 weeks apart, 
to meet diagnostic criteria)10 
• Anticardiolipin immunoglobulin G (IgG) or 
immunoglobulin M (IgM) antibodies greater than 
99th percentile 
• Antibeta2-glycoprotein I IgG or IgM antibodies 
greater than 99th percentile 
• The presence of lupus anticoagulant 
The factors that affect the decision, to provide 
Thromboprophylaxis, as well as the timing (antenatal or 
postpartum only) and intensity of therapy depends on the 
following: 
• Any prior personal history of VTE 
• The presence of high- versus low-risk 
thrombophilia 
• The setting in which a prior VTE occurred 
(pregnancy/estrogen-related, idiopathic, or in the 
setting of non-recurrent risk factors such as 
fractures, surgery, or immobilization) 
Early recognition of risk factors and judicious 
implementation of Thromboprophylaxis has significantly 
decreased maternal mortality due to thromboembolism 
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